Netherlands· NL-322fdf263056

Campral 333 mg, maagsapresistente tabletten

A acamprosate product containing acamprosaat calcium, registered in Netherlands by Euro Registratie Collectief B.V.. The same ATC class is registered in 14 of our 19 countries.

ATC N07BB03

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about acamprosaat calciumAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Acamprosate is registered in 14 of 19 countries.

Countries holding a registration under ATC N07BB03 (acamprosate), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
8 of them publish a price we can compare per daily dose

Search acamprosate products by name

Acamprosate · ATC N07BB03

14 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Franceprice
Germany
Ireland
Italyprice
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of acamprosate costs, country by country.

Normalised to the WHO defined daily dose (2 g), the median price runs from $1.14 in France to $3.37 in Switzerland — a ×3.0 gap.

3 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Acamprosate · price per daily dose (2 g)

USD · FX 28 Sept 2026

CH Switzerland$3.37
IT Italy$2.75
FR France$1.14

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: ACAMPROSAAT CALCIUM
Manufacturer: Euro Registratie Collectief B.V.
Country: Netherlands (NL)
ATC code: N07BB03
ATC class: Acamprosate
Defined daily dose: 2 g, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
114554//18220

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

19 interactions on record for acamprosate.

Graded by severity as the source publishes them — 19 info. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check acamprosate against other medicines How interaction checks work

Acamprosate · interactions on record

19 records

19 info

Most severe, free to view

Mechanism and what to do, in the interaction check

Interaction register. Grades as the source publishes them.

Same medicine, other countries

Acamprosate in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All acamprosate products

Authorised across Europe · EMA

The same active substance is authorised in 15 EEA countries. Names it is sold under:

Austria · Campral
Belgium · Campral
Czechia · Campral
Germany · Campral
Spain · Campral
France · Acamprosate Biogaran, Acamprosate Viatris
United Kingdom (Northern Ireland) · Acamprosate Generics [uk] Ltd, Acamprosate Strandhaven Somex Pharma
Ireland · Campral Ec
Italy · Campral
Luxembourg · Campral
Norway · Campral
Poland · Campral
Portugal · Campral
Sweden · Akamprosat Viatris, Campral
Slovakia · Acamprosat Viatris, Campral

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/dc99386e-7b81-4293-bbf5-9126166ed43d
GET /v1/drugs/dc99386e-7b81-4293-bbf5-9126166ed43d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Maagsapresistente tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h18220_smpc.pdf",
  "strength": null,
  "atc_label": "Acamprosate",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg114554",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "COPOLYMEER VAN ETHYLACRYLAAT-METHACRYLZUUR (1:1)",
    "CROSPOVIDON (E 1202)",
    "MAGNESIUMSILICAAT (E 553a)",
    "MAGNESIUMSTEARAAT (E 470b)",
    "NATRIUMZETMEELGLYCOLAAT",
    "PROPYLEENGLYCOL (E 1520)",
    "SILICIUMDIOXIDE (E 551)",
    "TALK (E 553b)"
  ],
  "substances": [
    "ACAMPROSAAT CALCIUM"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h114554.pdf",
  "authorised_at": "2013/12/04",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "114554//18220",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about acamprosate.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console